Pacific Biomarkers, WuXi PharmaTech Ink Biomarker Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biomarkers will provide access to its validated biomarker assays to WuXi PharmaTech under a collaboration announced today.

As part of the deal, Pacific Biomarkers will provide its biomarkers to support Shanghai-based WuXi's integrated clinical trial testing services, including bioanalysis and central laboratory services for drugmakers and biotech firms doing clinical drug development in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.